Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Feb 13;209(2):395–406. doi: 10.1084/jem.20110216

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2012 Alkhatib et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 5. — Inhibition of PI3K leads to expression of Ikaros and to μHC generation. (A) Immunoblot analysis of FoxO1, Ikaros, and μHC expression in Pten-deficient cells treated with either DMSO or the PI3K inhibitor LY294002. Immunoblotting for actin served as loading control. (B) Flow cytometric analysis of µHC expression in Pten-deficient cells treated with either DMSO or the PI3K inhibitor LY294002. (C) Flow cytometric analysis for µHC and GFP expression of Pten-deficient cells transduced with an EV or an expression vector encoding dominant-negative Ikaros (IK6) and treated with LY294002. (D) Immunoblot analysis for Ikaros expression in SLP-65–deficient pre–B cells treated with DMSO or the PI3K inhibitor LY294002. Immunoblotting for actin served as loading control. (E) Immunoblot analysis for Ikaros expression in SLP-65–deficient pre–B cells transduced with 4-hydroxytamoxifen (4-OHT)–inducible forms of either SLP-65 (ER^T2-SLP65) or FoxO1-A3 (ER^T2-FoxO1-A3). Upon sorting of positively transduced cells, the cells were treated with the solvent ethanol (−) or 4-OHT (+) to activate ER^T2-SLP65 and ER^T2-FoxO1-A3. Immunoblotting for actin served as loading control. (F) Top, FACS plots for κLC expression in SLP-65–deficient pre–B cells transduced with an EV or with an Ikaros expression vector. Cells were cultured in the presence of IL-7. Bottom, dot plots for κLC expression in SLP-65–deficient pre–B cells transduced with an EV or with an expression vector for DN-Ikaros (IK6); both were treated with the PI3K inhibitor LY294002. Numbers in quadrants indicate percentages of cells in the respective region. Data are representative of at least two to three independent experiments.